| Title: |
Bugs as Cancer Drugs, Challenges and Opportunities. |
| Authors: |
Daschner, Phillip J.1, Rasooly, Avraham2, White, Jeffrey D.2 |
| Source: |
Molecular & Cellular Biology. Aug2019, Vol. 39 Issue 15, p1-4. 4p. |
| Subject Terms: |
*CANCER treatment, *CANCER, *DRUGS |
| Company/Entity: |
NATIONAL Cancer Institute (U.S.) |
| Abstract: |
The first nonsurgical cancer therapy was bacterial therapy introduced in 1891 to treat solid tumors. Because in many cases it was harmful and ineffective, and with the emergence of radiotherapy and chemotherapy, bacterial therapy was discontinued. Motivated by the need to improve targeting of solid tumors and in light of recent progress made in developing microbial therapies, the National Cancer Institute has for the first time issued funding opportunities to stimulate research on bacterial-based cancer therapies for conditions in which current cancer therapies are inadequate. [ABSTRACT FROM AUTHOR] |
|
Copyright of Molecular & Cellular Biology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
